MAP2K7 and non-small cell lung carcinoma: This has been shown by successful treatment of endothelial growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with EGFR inhibitors, treatment of breast cancer gene (BRCA)-mutated ovarian cancer with poly-ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitors and treatment of BRAF-mutated cutaneous melanoma and NSCLC with BRAF inhibitors or MEK inhibitors [8,9,10,11].